DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20213754

Berbamine application beyond cancer

Navneet O. Soni

Abstract


The main purpose of this review was to ascertain the clinical application and future non oncological uses of Berbaminebamine (BERBAMINE). Berbaminebamine, as a STAT3 (signal transducer and activator of transcription) inhibitor, antioxidant, anti-inflammatory and modulator of many signalling pathways, should be investigated in autoimmune diseases.  Berbaminebamine has been found to have pharmacological activity in the following cancers: breast cancer, lung cancer, prostate cancer, pancreatic cancer, ovarian cancer, glioblastoma, colon cancer, bladder cancer, chronic myeloid leukemia, hepatocellular carcinoma, triple negative breast cancer and osteosarcoma. Ischemic reperfusion injury, melanoma, COVID-19 and allergy diseases are among the conditions for which it is beneficial. It may aid in the treatment of obesity, metabolic syndrome, inflammatory syndrome, sepsis, COVID-19, dengue fever, Nipah virus infection, influenza, solid tumors, lymphoma, cancer, hematological malignancies, skin inflammatory disorder and atopic dermatitis.  BERBAMINE can be used as versatile molecule in alcoholic liver disease, diabetic nephropathy and antiviral, anti-inflammatory.


Keywords


Cancer, Diabetic nephropathy, Anti-inflammatory, Reperfusion injury, COVID-19

Full Text:

PDF

References


Cheng XX, Lui Y, Zhou B, Xiao XH, Liu Y. Probing the binding sites and the effect of berbamine on the structure of bovine serum albumin. Spectrochim Acta A Mol Biomol Spectrosc. 2009;72(5):922-8.

Wang S, Liu Q, Zhang Y, Liu K, Yu P, Liu K, et al. Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by Berbamine and its molecular mechanisms of action. Mol Cancer. 2009;8(1):1-5.

Meng Z, Li T, Ma X, Wang X, VanNess C, Gan Y, et al. Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca2+/calmodulin-dependent protein kinase II. Mol Cancer Therapeut. 2013;12(10):2067-77.

Wang S, Liu Q, Zhang Y, Liu K, Yu P, Liu K, et al. Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by Berbamine and its molecular mechanisms of action. Mol Cancer. 2009;8(1):1-5.

Hou ZB, Lu KJ, Wu XL, Chen C, Huang XE, Yin HT. In vitro and in vivo antitumor evaluation of berbamine for lung cancer treatment. Asian Pac J Cancer Prevent. 2014;15(4):1767-9.

Zhao Y, Lv JJ, Chen J, Jin XB, Wang MW, Su ZH, et al. Berbamine inhibited the growth of prostate cancer cells in vivo and in vitro via triggering intrinsic pathway of apoptosis. Prostate Cancer Prostatic Dis. 2016;19(4):358-66.

Hu B, Cai H, Yang S, Tu J, Huang X, Chen G. Berbamine enhances the efficacy of gefitinib by suppressing STAT3 signaling in pancreatic cancer cells. Onco Targets Ther. 2019;12:11437.

Zhang H, Jiao Y, Shi C, Song X, Chang Y, Ren Y, et al. Berbamine suppresses cell proliferation and promotes apoptosis in ovarian cancer partially via the inhibition of Wnt/β-catenin signaling. Acta Biochimica Biophysica Sinica. 2018;50(6):532-9.

Yang F, Nam S, Brown CE, Zhao R, Starr R, Horne DA, et al. A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via up-regulation of miRNA-4284 and JNK/AP-1 signaling. PloS one. 2014;9(4):94443.

Mou L, Liang B, Liu G, Jiang J, Liu J, Zhou B, et al. Berbamine exerts anticancer effects on human colon cancer cells via induction of autophagy and apoptosis, inhibition of cell migration and MEK/ERK signaling pathway. J BUON. 2019;24(5):1870-5.

Han C, Wang Z, Chen S, Li L, Xu Y, Kang W, et al. Berbamine suppresses the progression of bladder cancer by modulating the ROS/NF-κB axis. Oxidat Med Cell Longe. 2021.

Nam S, Xie J, Perkins A, Ma Y, Yang F, Wu J, et al. Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. Mol Oncol. 2012;6(5):484-93.

Kapoor S, Liang Y, Qiu X, Xu RZ, Zhao XY. Emerging role of berbamine as an anti-cancer agent in systemic malignancies besides chronic myeloid leukemia. J Zhejiang Univ. 2012;13(9):761.

Zhu L, Zhang B, Lu X, Shu Y, Liu B. Delivery of paclitaxel and berbamine by polymeric carriers to cure gastric cancer. Preclinic Clinic Cancer Therapeut. 2013;20(7):265-74.

Zhang H, Jiao Y, Shi C, Song X, Chang Y, Ren Y, et al. Berbamine suppresses cell viability and induces apoptosis in colorectal cancer via activating p53-dependent apoptotic signaling pathway. Cytotechnol. 2018;70(1):321-9.

Wang GY, Lv QH, Dong Q, Xu RZ, Dong QH. Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice. J Asian Nat Prod Res. 2009;11(3):219-28.

Zhu H, Ruan S, Jia F, Chu J, Zhu Y, Huang Y, et al. In vitro and in vivo superior radiosensitizing effect of berbamine for head and neck squamous cell carcinoma. Onco Target Ther. 2018;11:8117.

Liu L, Xu Z, Yu B, Tao L, Cao Y. Berbamine inhibits cell proliferation and migration and induces cell death of lung cancer cells via regulating c-Maf, PI3K/Akt, and MDM2-P53 pathways. Complement Alternat Med. 2021.

Zhang H, Zhu T, Fu R, Peng Y, Jing P, Xu W, et al. Combination of detoxified pneumolysin derivative ΔA146Ply and berbamine as a treatment approach for breast cancer. Mol Ther Oncolytic. 2020;18:247-61.

Jia XJ, Li X, Wang F, Liu HQ, Zhang DJ. Berbamine exerts anti-inflammatory effects via inhibition of NF-κB and MAPK signaling pathways. Cell Physiol Biochem. 2017;41(6):2307-18.

Wang GY, Zhang JW, Lü QH, Xu RZ, Dong QH. Berbamine induces apoptosis in human hepatoma cell line SMMC7721 by loss in mitochondrial transmembrane potential and caspase activation. J Zhejiang Univ. 2007;8(4):248-55.

Kapoor S, Liang Y, Qiu X, Xu RZ, Zhao XY. Emerging role of berbamine as an anti-cancer agent in systemic malignancies besides chronic myeloid leukemia. J Zhejiang Univ. 2012;13(9):761.

Yang S, Yang S, Zhang H, Hua H, Kong Q, Wang J, et al. Targeting Na+/K+‐ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma. Bri J Pharmacol. 2021.

Tyler J. Natural product berbamine enhances the efficacy of doxorubicin treatment for triple negative breast cancer. Univ Ther. 2020:5763.

Wei YL, Xu L, Liang Y, Xu XH, Zhao XY. Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo. Acta Pharmacologica Sinica. 2009;30(4):451-7.

Zhao Y, Tan Y, Wu G, Liu L, Wang Y, Luo Y, et al. Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia. Int J Hematol. 2011;94(2):156-62.

Yang S, Yang S, Zhang H, Hua H, Kong Q, Wang J, et al. Targeting Na+/K+‐ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma. Br J Pharmacol. 2021.

Xu R, Dong Q, Yu Y, Zhao X, Gan X, Wu D, et al. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leukemia Res. 2006;30(1):17-23.

Yang F, Nam S, Zhao R, Tian Y, Liu L, Horne DA, et al. A novel synthetic derivative of the natural product Berbamine inhibits cell viability and induces apoptosis of human osteosarcoma cells, associated with activation of JNK/AP-1 signaling. Cancer Biol Ther. 2013;14(11):1024-31.

Ling-Jun H, Ting-Yi J, Chao P, Wan-Lin W, Chang DM, Chang SY, et al. Plant alkaloid tetrandrine downregulates I [kappa] B [alpha] kinases-I [kappa] B [alpha]-NF-[kappa] B signaling pathway in human peripheral blood T cell. Br J Pharmacol. 2004;143(7):919.

Zhang CM, Gao L, Zheng YJ, Yang HT. Berbamine protects the heart from ischemia/reperfusion injury by maintaining cytosolic Ca2+ homeostasis and preventing calpain activation. Circul J. 2012;76(8):1993-2002.

Jia F, Ruan S, Liu N, Fu L. Synergistic antitumor effects of berbamine and paclitaxel through ROS/Akt pathway in glioma cells. Complement Alternat Med. 2017.

Xin-Yu LI, Guan-Nan CH, Guo-Ming DU, Yue PA, Wu-Qi SO, Jiang TW, et al. Berbamine ameliorates ethanol-induced liver injury by inhibition of hepatic inflammation in mice. Chinese J Nat Med. 2020;18(3):186-95.

Nam S, Xie J, Perkins A, Ma Y, Yang F, Wu J, et al. Novel synthetic derivatives of the natural product Berbamine inhibit JAK2/STAT3 signaling and induce apoptosis of human melanoma cells. Mol Oncol. 2012;6(5):484-93.

Xu H, Kong Y, Chen Y, Li N, Zhang S, Lu H. Natural plant extract berbamine is a potent inhibitor of cell growth and survival of human tenon’s fibroblasts. Ophthal Res. 2020;63(6):555-63.

Kim YJ, Han JM, Jung HJ. Antiangiogenic and antitumor potential of berbamine, a natural CaMKIIγ inhibitor, against glioblastoma. Biochem Biophys Res Communic. 2021;566:129-34.

Huang L, Yuen TT, Ye Z, Liu S, Zhang G, Chu H, et al. Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2. Signal Transduct Target Ther. 2021;6(1):1-3.

Teh BS, Seow WK, Li SY, Thong YH. Inhibition of prostaglandin and leukotriene generation by the plant alkaloids tetrandrine and Berbamine. Int J Immunopharmacol. 1990;12(3):321-6.

Sharma A, Anand SK, Singh N, Dwivedi UN, Kakkar P. Berbamine induced AMPK activation regulates mTOR/SREBP-1c axis and Nrf2/ARE pathway to allay lipid accumulation and oxidative stress in steatotic HepG2 cells. Eur J Pharmacol. 2020;882:173244.

Hudson AM, Lockard GM, Namjoshi OA, Wilson JW, Kindt KS, Blough BE, et al. Berbamine analogs exhibit differential protective effects from aminoglycoside-induced hair cell death. Front Cell Neurosci. 2020;14:234.

Zheng Y, Gu S, Li X, Tan J, Liu S, Jiang Y, et al. Berbamine postconditioning protects the heart from ischemia/reperfusion injury through modulation of autophagy. Cell Death Dis. 2017;8(2):2577.

Zheng Y, Gu S, Li X, Tan J, Liu S, Jiang Y, et al. Berbamine postconditioning protects the heart from ischemia/reperfusion injury through modulation of autophagy. Cell Death Dis. 2017;8(2):e2577.

Soni NO. Biodegradable nanoparticles for delivering drugs and silencing multiple genes or gene activation in diabetic nephropathy. Int J Life Sci Scienti Res. 2017;3(5):1329-38.

Soni NO. Drugs for diabetic nephropathy-full review. World J Pharm Pharmaceut Sci. 2017;6(7):1958-2022.

Soni NO. Embryonic life of HDACs inhibitor-in diabetic nephropathy. World J Pharm Pharmaceutical Sci. 2017;6:345-59.

Soni NO. TRPC 6 as a molecular target in diabetic nephropathy. Int J Life Sci Scienti Res. 2017;3(5):1311-4.

Soni NO. Resveratrol nanoparticle's formulation-in diabetic nephropathy. World J Pharm Pharmaceut Sci. 2017:368-86.

Soni NO. Targeting DNA methyl transferase 1 [DNMT1]-in diabetic nephropathy. World J Pharma Pharma Sci. 2017;6(9):333-8.

Soni NO. Monaschin and ankaflavin-in diabetic nephropathy? World J Pharma Pharma Sci. 2017;6(9):327-2.

Soni NO, Pawar SV, Kale S, Mane UA, Bhosale PU, Phandhare K, et al. Peroxisome proliferator-activated receptors and thiazolidinediones in diabetic nephropathy. Int J Basic Clinic Pharmacol. 2019;8(10):2344.

Soni NO. Fructokinase inhibitors–in diabetic nephropathy. World J Pharma Pharma Sci. 2017;6(9).

Soni NO. FAP inhibitors: in diabetic nephropathy?. World J Pharma Pharma Sci. 2017;6(9):321-6.

Soni NO. Recombinant complement inhibitor CD59–in diabetic nephropathy. In Diabetic Nephropathy. 2017;6(7):2056-60.

Soni NO. Current and future clinical application. Phosphodiesterase (PDEs). Inhibitors. 2017;8(7):1612-32.

Soni NO. A brief study about HDACs: Novel Pharmacological Target in diabetic nephropathy. New Forntiers Med Med Res. 2021;25:26-34.

Soni NO. NADPH oxidase is novel drug in diabetic nephropathy. World J Pharm Pharmaceutical Sci. 2017;6:765-5.

Soni NO. TGF-inhibitors are novel drugs-in diabetic nephropathy a review. World J Pharm Pharmaceut Sci. 2017:622-45.

Huang L, Lin T, Shi M, Chen X, Wu P. Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt/β-catenin signaling. Am J Physiol Renal Physiol. 2020;319(3):458-68.

Zhang L, Pang S, Deng B, Qian L, Chen J, Zou J, et al. High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF-κB/NADPH oxidase/ROS pathway, which is inhibited by resveratrol. Int J Biochem Cell Biol. 2012;44(4):629-38.

Salatto CT, Miller RA, Cameron KO, Cokorinos E, Reyes A, Ward J, et al. Selective activation of AMPK β1-containing isoforms improves kidney function in a rat model of diabetic nephropathy. J Pharmacol Experiment Therapeut. 2017;361(2):303-11.

Zheng C, Huang L, Luo W, Yu W, Hu X, Guan X, et al. Inhibition of STAT3 in tubular epithelial cells prevents kidney fibrosis and nephropathy in STZ-induced diabetic mice. Cell Death Dis. 2019;10(11):1-4.

Wei M, Li Z, Xiao L, Yang Z. Effects of ROS-relative NF-κB signaling on high glucose-induced TLR4 and MCP-1 expression in podocyte injury. Mol Immunol. 2015;68(2):261-71.

Wen D, Tan RZ, Zhao CY, Li JC, Zhong X, Diao H, et al. Astragalus mongholicus Bunge and Panax notoginseng (Burkill) FH chen formula for renal injury in diabetic nephropathy-in vivo and in vitro evidence for autophagy regulation. Front Pharmacol. 2020;11:732.

Soni NO. Stat protein–a molecular target in asthma. History. 2016;3:4.

Soni NO. Nuclear factor-kappa-b–as molecular target in asthma. World J Pharma Pharma Sci. 2017;5(7):481-98.